13F Insight
DOSSIER · 13F-HR · Q2 2026

General Catalyst Group Management, LLC

$189M in tracked AUM across 14 positions as of Q2 2026.

GC
CIK 0001637946 · last filed Jun 30, 2026
Total AUM
$189M
as of Q2 2026
Holdings
14
—
positions
Whale Score
71
71
strong
Activity
—
no data
changes this Q
AI Analysis · Q2 2026

Based on the SEC 13F filing data provided for General Catalyst Group Management, LLC as of September 30, 2025, here is a comprehensive financial analysis.

1. Portfolio Overview

The filing reveals a dramatic restructuring of General Catalyst’s reported 13F portfolio, characterized by a massive reduction in assets under management and a pivot toward extreme concentration. The total portfolio value plummeted by 90.2%, decreasing from $4.30 billion to $421.48 million quarter-over-qu...

2. Key Holdings

The portfolio is dominated by a single position, Samsara Inc. (IOT), which comprises 81.76% of the total portfolio value at approximately $344.60 million. Despite being the largest position, the manager reduced this stake by 22.8% (selling $132.02 million worth of shares), indicating a desire to realize profits while maintaining a dominant foothold in the company.

The remaining holdings are significantly smaller in scale. GitLab Inc. (GTLB) represents 9.86% of the portfolio ($41.54M), and Arrivent Biopharma Inc accounts for 6.54% ($27.58M). Fractyl Health Inc makes up the tail of the portfolio at 1.84% ($7.77M). The disparity between the top holding and the rest of the portfolio is stark, with Samsara being worth roughly 8.3 times more than the second-largest holding, GitLab.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
AVBP
ArriVent BioPharma, Inc.
$52M1.5M27.5%02
PBLS
Parabilis Medicines, Inc.
$44M1.6M23.2%03
CART
Maplebear, Inc.
$34M711K17.9%04
MAZE
Maze Therapeutics, Inc.
$31M1.0M16.4%05
ODTX
Odyssey Therapeutics, Inc.
$15M810K8.0%06
EIKN
Eikon Therapeutics, Inc.
$4M305K2.1%07
GUTS
Fractyl Health, Inc.
$4M4.9M2.1%08
LIFE
Ethos Technologies, Inc.
$1M74K0.7%09
CPNG
Coupang Inc.
$950K55K0.5%10
AMZN
Amazon.com Inc.
$925K4K0.5%

Filing history

2026Q2Jun 30
$189M▲ 2.7%
14 positionsView →2026Q1Mar 31
$184M▼ 17.2%
12 positionsView →2025Q4Dec 31
$222M▼ 47.4%
7 positionsView →2025Q3Sep 30
$421M▼ 90.2%
4 positionsView →2025Q2Jun 30
$4.3B▲ 450.1%
10 positionsLocked2025Q1Mar 31
$781M▼ 31.5%
7 positionsLocked2024Q4Dec 31
$1.1B▼ 20.3%
11 positionsLocked2024Q3Sep 30
$1.4B▲ 23.4%
11 positionsLocked2024Q2Jun 30
$1.2B▼ 10.7%
11 positionsLocked2024Q1Mar 31
$1.3B▲ 2.1%
11 positionsLocked2023Q4Dec 31
$1.3B▲ 20.8%
10 positionsLocked2023Q3Sep 30
$1.1B▼ 15.7%
11 positionsLocked
Showing 12 of 25